Gonadorelin Trial NCT07340619 Registered, Not Yet Recruiting

On August 3, 2026, a new clinical trial record involving gonadorelin was posted to ClinicalTrials.gov under identifier NCT07340619. The trial is titled 'Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.' The study is registered as Phase 2 and its current status is listed as not yet recruiting. No participant enrollment has begun as of the listed date. The registration provides the trial title, phase, and status as stated on ClinicalTrials.gov, without additional detail on design or outcome measures at this time. No results have been posted for this trial, and none should be assumed based on this registration alone. Gonadorelin remains an approved compound, and this listing reflects only the administrative posting of a new study record. Readers should note that trial status can change as studies progress toward recruitment and eventual data collection. For further background on gonadorelin, readers can consult the compound overview.